In home health care the insurer holds the cheque, so four agencies sold straight to that buyer while two collapsed on debt and paper. Six case studies.
Home Health Care Case Studies
Case 1
These home health care case studies look at six real businesses, and something about them is different from every other story in this collection. Four ended with a bigger company buying them out. Two show what happens when that buyer never shows up.
Here's what makes this industry strange. In most businesses, the customer decides what to buy, and pays for it themselves. Home health care doesn't work that way. A patient gets the visit, sure, but a doctor orders it, and the actual bill goes to Medicare, Medicaid, or an insurance company. That means the real customer isn't the patient at all. It's the payer, whoever is footing the bill.
That one fact explains everything in the six stories ahead. The four winners below didn't necessarily win by giving better care than everyone else. They won by becoming attractive enough for a payer, or a bigger company, to want to buy them.
The two failures show the flip side of that same setup, one built its whole business around a sale that never happened, and the other watched a massive $3.6 billion merger fall apart because someone else made a better offer.
Case Study 1: Amedisys, the Home Health Referral Network That Took 41 Years to Reach a $3.3 Billion Exit
Forty-one years. That's how long it took one company to build something most people never even think about, trust. Not trust with patients directly, but trust with thousands of hospitals and doctors, the people who decide where patients go for care after leaving the hospital.
Amedisys spent four decades quietly building exactly that kind of trust. In the end, it turned into a $3.3 billion payday.
About the Business
Type: A company that provides home health care, hospice care, palliative care, and high-level medical care at home. It used to trade on the stock market under the name AMED.
Founded/Launched: Started in 1982, in Baton Rouge, Louisiana. It later added an office in Nashville too. UnitedHealth's division, Optum, bought the company, and that deal closed in August 2025.
Revolution: Amedisys proved something important. In a business where insurance companies pay the bills, not patients themselves, the most valuable thing you can build isn't your staff. It's your network of relationships with hospitals and doctors. And the most likely buyer for that network turns out to be the insurance company itself.
Here's something unusual about home health care. A company can't just go find new patients on its own, the way most businesses do. Every single patient arrives through a referral. That means a hospital worker or a doctor sends the patient to that company specifically.
So growth doesn't come from advertising to patients. It comes from building thousands of individual relationships with hospitals and doctors, one at a time. And often, competitors have already been building those same relationships for years.
Amedisys built its biggest advantage around something called a home health referral network. By the time it was acquired, more than 3,000 hospitals and 102,000 doctors across the country had already chosen Amedisys as their go-to partner for care after a hospital stay.
The company also grew by spreading out widely, instead of staying small and selective. By 2023, when the merger was first announced, Amedisys ran 522 care centers across 37 states, plus Washington, D.C., with about 16,500 employees working there.
That size mattered for one big reason. Amedisys served more than 465,000 patients every year, making over 11.2 million visits in total. That's exactly the kind of scale where an insurance company starts doing the math, and realizes it might save money by simply owning the company outright, instead of just paying it for services.
The Results
UnitedHealth bought Amedisys for $3.3 billion in cash. The deal finally closed in August 2025, after a two-year legal battle over antitrust concerns. On the day it closed, Amedisys stopped trading on the stock market completely.
At the time the deal closed, Amedisys was still serving more than 465,000 patients a year, across 38 states and Washington, D.C., before becoming part of UnitedHealth's Optum division.
Here's the big lesson from Amedisys' story. In a business paid for by insurance companies, the natural buyer is almost always the insurance company itself. Forty-one years spent building trust and relationships created something valuable, and its most eager buyer turned out to be the very same organization that was already paying for all that care.
Case 2
Case Study 2: LHC Group, the Home Health Agency That Sold for $5.4 Billion With Nobody Watching
Sometimes timing matters more than size. Eighteen months before UnitedHealth made headlines buying Amedisys, that exact same buyer paid considerably more money for a very similar business. And almost nobody noticed.
About the Business
Type: Home health and hospice provider operating in dozens of states.
Founded/Launched: Acquired by UnitedHealth in a deal that closed in 2023.
Revolution: Established the price a payer would pay for home health scale, and set the template the Amedisys deal followed.
Selling to an insurance company that's actively building out its own healthcare operations is very different from selling to a regular business competitor.
The buyer isn't just evaluating your business on its own. They're thinking about how it fits together with their own insurance arm. That's an entirely different kind of negotiation than selling to a strategic peer in the same industry.
LHC Group's biggest advantage came down to timing. As a home health agency, it made this deal before regulators started scrutinizing this exact type of acquisition much more closely. Because of that, the deal closed without any of the legal battles that followed later.
Scale mattered here too. LHC Group operated across dozens of different states, and that breadth is exactly what makes a home health agency genuinely useful to a national insurer, rather than one that only serves a single region.
Timing relative to regulators turned out to be everything. The deal was completed in 2023, more than a full year before the Department of Justice actually sued to block the very same buyer's next acquisition attempt.
The Results
UnitedHealth acquired LHC Group for $5.4 billion, an even larger sum than what it later paid for Amedisys, a deal that ended up generating far more public attention and coverage.
The acquisition gave Optum home health and hospice operations across dozens of states, all before the Amedisys deal was even publicly announced.
Here's the real lesson behind LHC Group's exit. Being early to a buyer is often worth more than simply being the better business. The exact same acquirer paid $2.1 billion more for LHC Group than it later paid for Amedisys, and closed that earlier deal without a single lawsuit standing in the way.
Case 3
Case Study 3: Optum, the Buyer of Home Health Providers That Became the Biggest Without Building One
The most successful company in home health care isn't actually a home health company at all. It's an insurance company. This company bought two separate businesses, and according to experts, it ended up becoming the biggest home health provider in the entire country, without ever building a single new location from scratch.
About the Business
Type: Health services division of UnitedHealth Group, acquiring home health and hospice providers.
Founded/Launched: Acquired LHC Group (2023) and Amedisys (announced 2023, closed August 2025).
Revolution: Optum proved something important. In a business where insurance companies pay for the care, the most money doesn't go to whoever actually delivers that care. It goes to whoever owns both sides, the payment side and the care side, at the same time.
Buying the exact companies you also pay money to is exactly the kind of deal that government regulators pay close attention to.
In November 2024, the Department of Justice sued to try to stop the Amedisys deal, arguing it would seriously hurt competition for these services across hundreds of markets in the United States.
Optum didn't just buy one company. It bought two. First came LHC Group, for $5.4 billion. Then came Amedisys, for $3.3 billion. Together, these deals gave Optum coverage of home health providers across the whole country, built through buying, not building.
Getting the Amedisys deal done wasn't quick or easy. It took a long time, and the two sides finally reached an agreement with the Department of Justice on August 7, 2025. A judge approved that agreement just a few days later.
That agreement came at a real cost, though. Instead of walking away from the deal completely, Optum agreed to sell off 164 home health and hospice locations. That's the trade Optum made in exchange for getting government approval.
The Results
In total, Optum spent $8.7 billion across both deals combined. The Amedisys purchase officially closed in August 2025.
Because of these two deals, UnitedHealth became a major player in home health and hospice care, possibly even the biggest one in the whole country, according to industry experts. Still, some analysts pointed out that Amedisys itself would likely only add a small amount to the company's overall profits.
Here's the big lesson behind Optum's rise. This kind of growth, where one company owns both the payment side and the care side of a business, usually gets bought, not built from scratch. The real value doesn't come from home health profits alone. It comes from how the insurance side and the actual care side work together, which is exactly why the Department of Justice objected so strongly in the first place.
Case 4
Case Study 4: Option Care Health, the Home Infusion Therapy Business That Stayed Independent
While insurance companies were busy buying up home health agencies across the country, one company in a closely related field did something different. It grew into the largest independent player in home infusion, without ever selling itself to an insurer along the way.
About the Business
Type: Home and alternate site infusion services provider (Nasdaq: OPCH), headquartered in Bannockburn, Illinois.
Founded/Launched: The nation’s largest independent provider of home and alternate site infusion services.
Revolution: Option Care Health proved that scale in home-based care is achievable without ever selling out to an insurance company, by building deep expertise in a specific clinical specialty, instead of just chasing referral relationships across a wide territory.
Home infusion is a demanding business to build. It requires pharmacists, nursing networks, and detailed clinical protocols in every single market a company operates in.
Building all of that on a national scale, while still staying independent from the insurers who reimburse for these services, is a much harder path to walk, by a wide margin.
Option Care Health's real advantage came from clinical depth. The company employed over 7,500 team members, including more than 4,500 clinicians, all working together across all 50 states.
Building expertise in home infusion therapy, rather than just controlling a geographic territory, made a real difference too. Infusion is a clearly defined clinical service, requiring its own trained workforce, which makes it much harder for a generalist buyer to simply copy or replicate.
The company also held onto real strategic ambition of its own. In May 2023, it agreed to combine with Amedisys in an all-stock deal, one that would have created a combined business with $6.2 billion in 2022 revenue.
The Results
Option Care Health remains independent and publicly listed today. Combined with Amedisys on a shared basis, the two companies generated more than $400 million in cash flow from operations during full-year 2022.
The company now serves patients with both acute and chronic conditions across all 50 states, standing as the largest independent operator in its entire category.
The real lesson behind Option Care Health's path is simple. Owning a clinical specialty acts as a real defense against being forced into a sale at a buyer's price. Staying independent in this industry is genuinely possible, and this case shows exactly what that independence actually costs to build.
Case 5
Case Study 5 (FAILED): Aveanna Healthcare, The IPO That Impaired Half a Billion Dollars
Perfect timing, or so it seemed. In April 2021, Aveanna went public during the best year for healthcare stock listings in a decade. Just twenty months later, the company had wiped out more than half a billion dollars in value, while owing $1.46 billion in bank debt, with only $19.2 million left in cash.
The Business
Aveanna Healthcare Holdings trades on the stock market under the ticker AVAH. It's a home care company that focuses on patients with serious, expensive medical needs. The business runs through two main parts, Private Duty Services and Home Health & Hospice.
The company sold shares to the public for the first time on April 28, 2021, pricing them at $12.00 each. It sold 38.2 million shares total, raising $432.4 million.
The “Bitter Pill” Details
Sales actually kept growing during this time. But almost everything else quietly fell apart underneath. In fiscal 2022, revenue climbed 6.5%, reaching $1,787.6 million. But profit margins shrank, dropping from 32.3% down to 30.9%. A key profit number called Adjusted EBITDA dropped hard too, falling from $184.2 million down to just $129.3 million.
The real damage, though, came from something much bigger, a massive write-down. This means the company had to officially admit that something it once valued highly was now worth far less. Aveanna reported a net loss of $662.0 million for fiscal 2022, compared to a loss of $117.0 million the year before. Most of that came from $557.6 million in extra, non-cash charges, with $87.4 million of that hitting in just the last three months of the year alone.
The company's finances left it almost no room to breathe. By the end of 2022, Aveanna owed $1,464.0 million in bank debt, but only had $19.2 million in cash. The company was actually losing money overall, $81.5 million in negative free cash flow for the year. And the maximum amount of debt its lenders would even allow had climbed to a risky 7.6 times its earnings.
The Financial Result
Here's the striking part. A company that had raised $432.4 million just eighteen months earlier ended up reporting a loss bigger than that entire amount.
Aveanna's own CEO pointed to things like "the labor environment" and future "reimbursement rate" improvements as reasons for hope, which really just meant the company's recovery depended entirely on decisions other people would make, not on anything Aveanna could control itself.
Here's the big lesson from Aveanna's story. In a business paid through government or insurance reimbursement rates, taking on heavy debt is really just a bet on a number you don't control. Aveanna's actual day-to-day business kept growing the whole time. What broke wasn't the business. It was the sky-high price paid to take it public, and the mountain of debt piled right on top of that price.
Case 6
Case Study 6 (FAILED): Option Care Health and Amedisys, The $3.6 Billion Merger That a Better Cheque Destroyed
On May 3, 2023, Option Care Health and Amedisys unveiled a deal that looked, in every way except the name, like a true merger of equals. Every number was worked out. Every detail was made public. And within just a few weeks, the whole thing fell apart.
The Business
This was a formal, all-stock merger agreement between Option Care Health and Amedisys. The deal valued Amedisys at roughly $3.6 billion, including debt the company already owed.
Here's how the numbers worked. Amedisys shareholders were set to receive 3.0213 shares of Option Care Health, for every single share of Amedisys they already owned. That worked out to $97.38 per share, a 26% premium above where Amedisys was trading at the time. Once combined, Option Care Health shareholders would have owned 64.5% of the new, merged company.
The “Bitter Pill” Details
On paper, this deal made a lot of sense. Together, the two companies would have created a national workforce of more than 16,500 healthcare professionals, running 674 care centers spread across 46 states. Combined, they would have brought in $6.2 billion in 2022 revenue, and $622 million in combined profit, called Adjusted EBITDA. The companies even projected saving around $75 million a year by the third year, thanks to combining operations.
But there was one big problem hiding inside the deal's structure. Because this was an all-stock deal, Amedisys shareholders weren't being offered cash. They were being offered shares in the new combined company instead, essentially paper, not money in hand. That left the whole agreement open to attack from any other buyer willing to pay in real cash instead, money that doesn't rise or fall in value the way stock can.
And that's exactly what happened. UnitedHealth's Optum swooped in with a better, higher offer. Amedisys walked away from the Option Care Health deal completely. The new deal it agreed to instead ended up taking two more full years to actually close, plus a lawsuit from the Department of Justice along the way.
The Financial Result
Option Care Health spent an entire three months announcing, explaining, and defending what it proudly called a transformational merger. It had already named the leadership team for the combined company. It had already picked the new headquarters location, right there in its original press release. And in the end, none of it actually happened.
Here's the big lesson from this whole story. A signed merger agreement is really just an option, not a guaranteed outcome, whenever the payment involved is stock instead of cash. Whoever has the deepest pockets ultimately gets to decide who buys the company. And in an industry paid for by insurance companies, that deepest pocket almost always belongs to the insurer itself.